1. Medtech Insight
  2. >>Business

Start-Up Spotlight: Aria CV Addresses Right-Heart Failure With Purely Mechanical Solution

 
• By Reed Miller

St. Paul-based Aria CV is developing a "passive" pulmonary artery balloon system to treat pulmonary hypertension and impede the development of heart failure. Following a successful first-in-human study, the company is currently developing a feasibility study it expects will lead to a US pivotal trial in several years.

Start-up Spotlight

Aria CV hopes to address pulmonary hypertension, a potentially devastating condition that currently has few treatments, with a unique balloon device that requires no power supply, battery, pump, or synchronization.

Pulmonary hypertension increases "afterload" on the right ventricle, which contributes to right-heart failure, but there are not many options to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Ellipsis Raises $45M To Expand AI Care Manager Across Health Systems

 
• By Marion Webb

Ellipsis said it will use its new funding to expand its AI-powered voice assistant Sage across health systems. Ellipsis is part of the global vocal biomarker market, which is expected to exceed $9bn by the end of 2033, according to a research market report.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

Sofinnova And NVIDIA Partner To ‘Supercharge’ Computation For European Startups

 
• By Natasha Barrow

European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

More from Medtech Insight